Effect of Isoniazid Preventive Therapy on the Incidence of Tuberculosis among Seropositive Children Attending HIV/AIDS Care in Two General Hospitals, Northwest Ethiopia, 2021

Table 2

Baseline clinical and laboratorial characteristics of seropositive children attending HIV/AIDS care in two general hospitals since 2015–2020 (N = 421).

Variables	Category	Total	Percentage
Hemoglobin	<10 mg/dl	147	34.92
	≥10 mg/dl	274	65.08
WHO stages	Stage I	128	30.4
	Stage II	147	34.92
	Stage III	89	21.14
	Stage IV	57	13.54
Functional status	Working	30	72.92
	Ambulatory	72	17.10
	Bedridden	42	9.98
CD4 levels	<100	30	7.13
	101–200	741	17.58
	≥201	317	75.3
ART regimen	4c = AZT+3 TC + NVP	255	60.5
	4d = AZT+3 TC + EFV	64	15.2
	1e = TDF+3 TC + EFV	70	16.62
	4g = TDF+3 TC + NVP	21	2.14
	4a = d4t+3 TC + NVP	9	4.99
	Others	2	0.48
Shift of the regimen	Yes	81	19.2
	No	340	80.76
Reasons for regimen change	Due to toxicity	24/81	29.63
	Due to TB	22/81	27.1
	New drug	5/81	6.17
	Clinical failure	23/81	28.9
	Immunological failure	7/81	8.64
Vaccination status	Fully vaccinated	328	77.91
	Defaulted	33	7.89
	Not started	60	14.25
CPT	Yes	316	75.06
	No	105	24.94
IPT	Yes	253	60.10
	No	168	39.9
Adherence status	Good	239	56.77
	Fair	118	28.03
	Poor	64	15.03
Opportunistic infection	Yes	126	29.93
	No	295	70.70
Follow-up	Alive and on follow-up	361	85.75
	Lost from follow-up	22	5.23
	Transfer out	29	6.88
	Died	9	2.14
MUAC	≤11.5 cm	145	34.44
	>11.5 cm	276	65.56
Underweight	No undernutrition	277	65.80
	Moderate undernutrition	115	27.32
	Severe undernutrition	29	6.89
Stunting	No stunting	284	67.46
	Moderate stunting	104	24.7
	Severe stunting	33	7.84
Wasting status	No wasting	304	72.21
	Moderate wasting	71	16.86
	Severe wasting	46	10.93